dc.contributor.author | Shali, H | |
dc.contributor.author | Shabani, M | |
dc.contributor.author | Pourgholi, F | |
dc.contributor.author | Hajivalili, M | |
dc.contributor.author | Aghebati-Maleki, L | |
dc.contributor.author | Jadidi-Niaragh, F | |
dc.contributor.author | Baradaran, B | |
dc.contributor.author | Akbari, AAM | |
dc.contributor.author | Younesi, V | |
dc.contributor.author | Yousefi, M | |
dc.date.accessioned | 2018-08-26T07:13:12Z | |
dc.date.available | 2018-08-26T07:13:12Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44904 | |
dc.description.abstract | Here, we investigated the effects of dual delivery of IGF-1R siRNA and doxorubicin by chitosan nanoparticles on viability of A549 lung cancer cells line by utilization of MTT and qRT-PCR. Furthermore apoptosis and migration of treated cells were assessed by Annexin-PI and wound healing assays, respectively. The chitosan nanoparticles had about 176nm size with zeta potential and polydispersive index about 11mV and 0.3, respectively. The IGF-1R siRNA had synergistic effect on DOX-induced cytotoxicity and apoptosis in tumour cells. In addition, siRNA/DOX-loaded chitosan nanoparticles could significantly decrease migration and expressions of mmp9, VEGF and STAT3 in A549 cells. | |
dc.language.iso | English | |
dc.relation.ispartof | ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY | |
dc.subject | Chitosan nanoparticle | |
dc.subject | doxorubicin | |
dc.subject | IGF-1R | |
dc.subject | lung cancer | |
dc.subject | ss siRNA | |
dc.title | Co-delivery of insulin-like growth factor 1 receptor specific siRNA and doxorubicin using chitosan-based nanoparticles enhanced anticancer efficacy in A549 lung cancer cell line | |
dc.type | Article | |
dc.citation.volume | 46 | |
dc.citation.issue | 2 | |
dc.citation.spage | 293 | |
dc.citation.epage | 302 | |
dc.citation.index | Web of science | |
dc.identifier.DOI | https://doi.org/10.1080/21691401.2017.1307212 | |